Log In
Print
BCIQ
Print
Print this Print this
 

MCLA-128

  Manage Alerts
Collapse Summary General Information
Company Merus B.V.
DescriptionAntibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced human common light chain bispecific IgG1 antibody targeting HER2 and HER3
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) ; Epidermal growth factor receptor 3 (EGFR3) (HER3) (ErbB3)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today